A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome

被引:0
|
作者
T. E. Woo
R. Lim
A. A. Heirali
N. Acosta
H. R. Rabin
C. H. Mody
R. Somayaji
M. G. Surette
C. D. Sibley
D. G. Storey
M. D. Parkins
机构
[1] University of Calgary,Department of Biological Sciences
[2] University of Calgary,Department of Medicine
[3] University of Calgary,Department of Microbiology, Immunology and Infectious Diseases
[4] McMaster University,Departments of Medicine, and Biochemistry and Biomedical Sciences
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A diverse microbiota exists within the airways of individuals with non-cystic fibrosis bronchiectasis (nCFB). How the lung microbiome evolves over time, and whether changes within the microbiome correlate with future disease progression is not yet known. We assessed the microbial community structure of 133 serial sputa and subsequent disease course of 29 nCFB patients collected over a span of 4–16 years using 16S rRNA paired-end sequencing. Interestingly, no significant shifts in the microbial community of individuals were observed during extended follow-up suggesting the microbiome remains relatively stable over prolonged periods. Samples that were Pseudomonas aeruginosa culture positive displayed markedly different microbial community structures compared to those that were positive for Haemophilus influenzae. Importantly, patients with sputum of lower microbial community diversity were more likely to experience subsequent lung function decline as defined by annual change in ≥−1 FEV1% predicted. Shannon diversity values <1 were more prevalent in patients with FEV1 decline (P = 0.002). However, the relative abundance of particular core microbiota constituents did not associate with risk of decline. Here we present data confirming that the microbiome of nCFB individuals is generally stable, and that microbiome-based measurements may have a prognostic role as biomarkers for nCFB.
引用
收藏
相关论文
共 50 条
  • [21] Update on non-cystic fibrosis bronchiectasis
    Bilton, Diana
    CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (06) : 595 - 599
  • [22] Management of non-cystic fibrosis bronchiectasis
    Webb, Philip
    King, Jenny
    Baxter, Caroline
    Lord, Robert W.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (07)
  • [23] Non-cystic fibrosis bronchiectasis in children
    Gursoy, Tugba Ramasli
    Eyuboglu, Tugba Sismanlar
    Aslan, Ayse Tana
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [24] Effect of obstructive airway disease in patients with non-cystic fibrosis bronchiectasis
    Khalid, M
    Saleemi, S
    Zeitouni, M
    Al Dammas, S
    Khaliq, MR
    ANNALS OF SAUDI MEDICINE, 2004, 24 (04) : 284 - 287
  • [25] Statins for non-cystic fibrosis bronchiectasis
    Feldman, Charles
    LANCET RESPIRATORY MEDICINE, 2014, 2 (06): : 431 - 432
  • [26] Treatment of Non-Cystic Fibrosis Bronchiectasis
    Martinez Garcia, Miguel Angel
    Maiz Carro, Luis
    Catalan Serra, Pablo
    ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (12): : 599 - 609
  • [27] Cough in non-cystic fibrosis bronchiectasis
    Kantar, Ahmad
    Song, Woo-Jung
    Bush, Andrew
    Chatziparasidis, Grigorios
    ERJ OPEN RESEARCH, 2024, 10 (06)
  • [28] Non-cystic fibrosis bronchiectasis Response
    Murray, Maeve P.
    Hill, Adam T.
    CLINICAL MEDICINE, 2009, 9 (04) : 402 - 402
  • [29] Management of Non-Cystic Fibrosis Bronchiectasis
    Dull, Stacey K.
    Havlat, Brooke D.
    Sanley, Michael J.
    Malesker, Mark A.
    CONSULTANT PHARMACIST, 2018, 33 (11): : 658 - 666
  • [30] Exacerbations in non-cystic fibrosis bronchiectasis
    Sahnoun, Imen
    Racil, Hajer
    Hafaied, Safa
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Chawech, Newel
    Mhiri, Emna
    Chabbou, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44